The American Gastroenterological Association has updated guidance for the treatment of ulcerative colitis to recommend using higher efficacy drugs in earlier stages of treatment, Medscape Medical News ...

In patients with ulcerative colitis, initiation of biologic therapy within 12 months of diagnosis is linked to a lower risk for disease progression than later initiation.

Switching UC treatments while managing a career and home life can be a major challenge. Here’s how to navigate work logistics ...

Ulcerative colitis (UC) is a chronic, immune-mediated inflammatory disorder of the colon that follows a relapsing-remitting course. Characterised by mucosal inflammation, the disease requires accurate ...

Aminosalicylate (5-ASA) therapy is often the first treatment option for patients presenting with mild to moderate ulcerative colitis (UC). Symptom improvements can be observed within 2 to 4 weeks ...

How Does Tremfya Work for Ulcerative Colitis? Tremfya is a monoclonal antibody that reduces inflammation. The main ingredient in Tremfya is a medicine called guselkumab. This medicine blocks a ...

Don't let insurance delays stall your ulcerative colitis remission. Learn how to navigate prior authorization, step therapy, and specialty pharmacy hurdles.

New ECCO dietary therapy guidelines for IBD clarify the role of enteral nutrition, Mediterranean diet, supplements, and RD ...

Please provide your email address to receive an email when new articles are posted on . A greater proportion of patients in the PRA023 group achieved clinical remission at 12 weeks vs. placebo (26.5% ...

T he goal of ulcerative colitis (UC) treatment is twofold: to heal the inflamed mucosal lining of the gut and to eliminate symptoms such as cramping and pain (usually once the inflammation subsides).

Nearly 70% of adolescents and young adults stop taking oral 5-aminosalicylic acid (5-ASA) maintenance therapy within 12 months of ulcerative colitis (UC) diagnosis, new research from the United ...